Atlas Trials

Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Clinical trial NCT06866548 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06866548
Sponsor
Shanghai Changzheng Hospital
Status
ACTIVE_NOT_RECRUITING
Phase
Early Phase 1
Study type
INTERVENTIONAL
mCRPC
Start date
2025-03-10
Primary completion
2025-11-11
Enrollment
7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.